araag2/HINT huggingface dataset:
Clinical trial NCT00151242 (phase 2/phase 3, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: cytarabine, idarubicin, etoposide, all-trans retinoic acid, pegfilgrastim
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed AML defined according to the World Health Organization
             (WHO)-classification (excluding acute promyelocytic leukemia [APL])

          -  Ages 18-60 years

          -  Written informed consent of each patient at study entry.

          -  Molecular and cytogenetical diagnostics on initial bone marrow and peripheral blood
             specimen at the central reference laboratories

        Exclusion Criteria:

          -  Bleeding independent of the AML

          -  Acute promyelocytic leukemia

          -  Uncontrollable infection

          -  Participation in a concurrent clinical study

          -  Insufficiency of the kidneys (creatinine > 1.5x upper normal serum level), of the
             liver (bilirubin, AST or AP > 2x upper normal serum level), severe obstructive or
             restrictive ventilation disorder, heart failure New York Heart Association (NYHA)
             III/IV

          -  Severe neurological or psychiatric disorder interfering with ability to give an
             informed consent.

          -  No consent for registration, storage and processing of the individual
             disease-characteristics and course.

          -  Performance status WHO > 2

          -  Pregnancy
Clinical trial NCT01338870 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, 25 mg pf-04991532, 75 mg pf-04991532, 150 mg pf-04991532, 300 mg pf-04991532, sitagliptin 100 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](CC1CCCC1)(N1C=NC(=C1)C(F)(F)F)C(O)=NC1=NC=C(C=C1)C(O)=O, [H][C@@](CC1CCCC1)(N1C=NC(=C1)C(F)(F)F)C(O)=NC1=NC=C(C=C1)C(O)=O, [H][C@@](CC1CCCC1)(N1C=NC(=C1)C(F)(F)F)C(O)=NC1=NC=C(C=C1)C(O)=O, [H][C@@](CC1CCCC1)(N1C=NC(=C1)C(F)(F)F)C(O)=NC1=NC=C(C=C1)C(O)=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

        Subjects with type 2 diabetes on stable doses of background medicines for management of
        diabetes; aged 18-70 years; body mass index between 22.5 and 45.5 kg/m2

        Exclusion Criteria:

        Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled
        blood pressure, significant kidney disease.
Clinical trial NCT00667758 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cetrorelix, placebo
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult between 18 years and above

          -  Moderate to severe disease activity

          -  Negative pregnancy test for women of childbearing potential

          -  Use of reliable method of contraception (non-hormonal) by sexually active female
             patients

        Exclusion Criteria:

          -  Patients who are pregnant or breastfeeding

          -  Patients taking biologic therapy or prednisolone >7.5mg
Clinical trial NCT00101101 (phase 2, status: active, not recruiting)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, il-2
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed mantle cell lymphoma

               -  Stage II, III, or IV disease

               -  Relapsed or de novo disease

          -  No symptomatic brain metastasis

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  White blood count (WBC) > 3,000/mm^3

          -  Absolute neutrophil count > 1,500/mm^3

          -  Platelet count > 100,000/mm^3

          -  Hematocrit > 25%

          -  Hemoglobin > 8 g/dL

        Hepatic

          -  Bilirubin < 2.0 mg/dL

        Renal

          -  Creatinine < 2.0 mg/dL OR

          -  Creatinine clearance > 60 mL/min

        Immunologic

          -  No serious ongoing infection

          -  No known HIV infection

          -  No other pre-existing immunodeficiency condition

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception for 1 month before, during, and for
             3 months after study treatment

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No other concurrent immunotherapy

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  More than 4 weeks since prior steroids

          -  No concurrent corticosteroids except as replacement doses in patients who are
             hypoadrenal

        Radiotherapy

          -  More than 2 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  No other concurrent immunosuppressive therapy
Clinical trial NCT00220272 (phase 2, status: completed)
Conditions: parkinson disease
ICD codes: G20
Drugs: sr57667b
SMILES: FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC=C(C=C2)C2=CC=CC=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients.

          -  Age >=35 years at screening.

          -  Diagnosis of Parkinson's syndrome, on at least two of the three key Parkinson's
             symptoms, i.e. resting tremor, bradykinesia and rigidity.

          -  Duration of the disease of less than 3 years since diagnosis.

          -  Modified Hoehn and Yahr stage <= 2.5.

          -  Patient optimized on monotherapy by levodopa or a dopamine agonist·

          -  Generally healthy and ambulatory.

          -  Patient has given his informed written consent and is capable of following study
             procedures.

        Exclusion Criteria:

          -  Any indication of forms of parkinsonism other than PD.

          -  Severe resting tremor. Presence of either dyskinesia, fluctuations, or loss of
             postural reflexes·

          -  Treatment with amantadine, anticholinergics, catechol-o-methyltransferase (COMT )
             inhibitors, selegiline, dopamine receptor antagonists, catecholamine depleters,
             indirect dopamine agonists or alphamethyldopa. Electroconvulsive therapy (ECT).Use of
             CYP3A4 strong, and moderate inducers or inhibitors. Participation in another clinical
             trial with an investigational drug within two months prior to randomization.

          -  Dementia, uncontrolled depression, psychotic disorder. History of substance-related
             disorders including alcohol or other substance use disorders.

          -  Females of child bearing potential.

          -  Evidence (detected by history, physical examination and/or laboratory/ECG tests) of
             any clinically significant or unstable medical disorder that could interfere with the
             patient's participation in the clinical trial; interfere with the absorption,
             metabolism or excretion of the study medication; or interfere with the evaluation of
             the study drug. Alterations of laboratory tests or ECG findings of potential clinical
             significance.
Clinical trial NCT00575874 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: rivoglitazone hcl, rivoglitazone hcl, rivoglitazone hcl, pioglitazone hcl, placebo
SMILES: COC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1, COC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1, COC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  type 2 diabetes

          -  HbA1c >6.5% and <10.0%

          -  FPG >126 mg/dL (7 mmol/L) and < 270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  History of ketoacidosis

          -  Current insulin therapy

          -  C-peptide <0.5ng/mL

          -  Imparied hepatic function

          -  NYHA Class II-IV cardiac status or hospitalization for CHF or EF<40%

          -  uncontrolled hypertension
Clinical trial NCT01256411 (phase 2, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: lcz696, amlodipine, hydrochlorothiazide (hctz)
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have successfully completed protocol No. CLCZ696A2219 and who, as judged
             by the study investigator, are able to continue in the current study.

          -  Ability to communicate and comply with all study requirements and demonstrate good
             medication compliance during CLCZ696A2219.

        Exclusion Criteria:

          -  Patients who did not complete CLCZ696A2219.

          -  Presence of significant protocol violation in CLCZ696A2219.

          -  Patients who are deemed to be unable to comply with the protocol by the investigator.

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00438568 (phase 2, status: completed)
Conditions: mild cognitive impairment, alzheimer's disease
ICD codes: G31.84, G30.8, G30.9, G30.0, G30.1
Drugs: regular insulin, placebo
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 55 or greater

          -  Good physical health

          -  Memory impairment with a diagnosis of mild cognitive impairment (MCI) or Alzheimer's
             disease (AD)

          -  Participants on stable doses of Memantine (Namenda) or cholinesterase inhibitors will
             be eligible

        Exclusion Criteria:

          -  Chronic sinus problems/allergies with chronic use of nasal decongestants or
             antihistamines

          -  Significant neurologic disease that might affect cognition (other than AD), such as
             stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of
             consciousness for more than 30 minutes or with permanent neurologic symptoms

          -  Significant medical illness or organ failure, such as uncontrolled hypertension or
             cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or
             kidney disease

          -  Preexisting diabetes or current or previous use of hypoglycemic agents or insulin;
             participants will be excluded if they have a fasting blood sugar greater than 165 on
             baseline OGTT

          -  Clinically significant elevations in liver function tests, cholesterol, or
             triglycerides

          -  Major psychiatric disorders (e.g., untreated major depression and schizophrenia)

          -  Chronic use of the following types of medications: anti-psychotic, anxiolytic, and
             opiates
Clinical trial NCT01081782 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: ono-4641, ono-4641, ono-4641, ono-4641 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male or female aged 18-55 years inclusive at screening

          -  Patients who have a definite diagnosis of relapsing-remitting Multiple Sclerosis

        Exclusion Criteria:

          -  Multiple Sclerosis course other than relapsing-remitting multiple sclerosis

          -  History of malignancy

          -  History of clinically significant chronic disease of the immune system (other than
             Multiple Sclerosis)

          -  Inability to undergo Gd-enhanced MRI scans

          -  Diagnosis of diabetes mellitus (type I or type II)
Clinical trial NCT01266135 (phase 2, status: terminated)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: qax576, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria

          -  Diagnosis of Idiopathic Pulmonary Fibrosis (IPF), based on an appropriate clinical
             definition of IPF as detailed in the ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary
             Fibrosis: Evidence-based Guidelines for Diagnosis and Management Diagnosis must be
             confirmed by a diagnostic HRCT or surgical lung biopsy.

          -  A 6-minute walk test (6MWT) distance ≥50 meters at Screening (use of supplemental
             oxygen allowed).

        Exclusion criteria

          -  Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will
             be measured during screening for all subjects. Smokers will be defined as any subject
             who reports tobacco use or has a urine cotinine levels in the range defined as
             'smokers' per the local lab.

          -  Lung residual volume > 120% predicted at Screening.
Clinical trial NCT01297335 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: clonidine
SMILES: ClC1=CC=CC(Cl)=C1NC1=NCCN1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Hypertension

          -  Stable systolic blood pressure >140 mmHg and < 190 mmHg

          -  On 3 or more antihypertensive medications

          -  On a diuretic

          -  Patients must be able to understand the risks

        Exclusion Criteria:

          -  Allergy to clonidine

          -  Presently on clonidine orally or transdermally

          -  Known or suspected correctable causes of secondary hypertension

          -  Breast Feeding or Pregnant women

          -  Unstable Ischemic Heart Disease

          -  Unstable Angina

          -  Intracoronary Stent Placement

          -  Coronary bypass within last 6 months

          -  Myocardial Infarction within last 6 months

          -  Congestive Failure

          -  Cardiac Arrhythmias

          -  Known Cerebral Vascular Disease

          -  Renal Disease

          -  Evidence of Injection Site Infection

          -  Known Bleeding Disorders

          -  Hepatic Insufficiency

          -  Renal Insufficiency

          -  Participation in an investigational drug study within 30 day of enrollment

          -  Prohibited Medications:

               -  Clonidine

               -  Yohimbine

               -  Tricyclic Antidepressants

               -  Mirtazapine

               -  Digitalis

               -  Reserpine

               -  Guanethidine

               -  Non-Steroidal Anti-inflammatory Medication

               -  Alcohol or Barbiturates within 48 hours of study procedure
Clinical trial NCT00457457 (phase 2, status: completed)
Conditions: prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: tamsulosin, uk-369,003
SMILES: CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O, CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Male subjects aged 40 years and above, with documented LUTS with an International
             Prostate Symptom Score (IPSS) ≥13

          2. Clinical diagnosis of BPH.

          3. Qmax 5 to 15ml/sec with a voided volume of ≥150ml at visit 1 (screening).

        Exclusion Criteria:

          1. Urinary tract infection

          2. Primary neurological conditions affecting bladder function
Clinical trial NCT01065051 (phase 2, status: terminated)
Conditions: hypertension, pulmonary, ventricular dysfunction, left
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22, I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1
Drugs: riociguat (adempas, bay63-2521), placebo
SMILES: COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients with symptomatic pulmonary hypertension due to left
             ventricular systolic dysfunction despite standard heart failure therapy

        Exclusion Criteria:

          -  Types of pulmonary hypertension other than group 2.1 of Dana Point Classification
Clinical trial NCT01266876 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: alirocumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Must meet the World Health Organization criteria for heFH

          2. Participants must be on a stable statin dose, with or without ezetimibe, for at least
             6 weeks before screening

          3. Serum LDL-C levels ≥ 100 mg/dL at screening

          4. Willing to follow the NCEP ATPIII TLC diet, or an equivalent diet plan, starting at
             screening and continuing until the last study visit

          5. A negative urine/serum pregnancy test at each screening visit and start of the study,
             for women of childbearing potential

        Key Exclusion Criteria:

          1. Participants with homozygous FH (clinically or by previous genotyping)

          2. Use of a medication (other than a statin or EZE) to alter serum lipids within 42 days
             (6 weeks) before screening including, but not limited to:

               -  Fibrates

               -  Niacin (>500 mg/day)

               -  Omega-3 fatty acids (>1000 mg/day of DHA/EPA)

               -  Bile acid resins

          3. Use of nutraceuticals or OTC medications that may alter lipid levels that are not
             stable for at least 6 weeks before screening and are not planned to remain constant
             throughout the study. Examples include:

               -  Omega-3 fatty acids (≤1000 mg/day of DHA/EPA)

               -  Niacin (≤500 mg/day)

               -  Plant stanols, such as found in Benecol, flax seed oil, psyllium

               -  Red yeast rice

          4. Disorders known to influence lipid levels, such as nephrotic syndrome, significant
             liver disease, Cushing's disease, untreated hypothyroidism (patients on stable thyroid
             replacement for at least 12 weeks before the full screening visit, who are
             metabolically euthyroid by thyroid-stimulating hormone (TSH) testing are allowed)

          5. Use of thyroid medications (except for replacement therapy which has been stable for
             at least 12 weeks before the full screening visit)

          6. Fasting serum TG >350 mg/dL screening

          7. LDL apheresis within 12 months before screening
Clinical trial NCT00424294 (phase 2, status: terminated)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cp-195,543, celecoxib, methotrexate
SMILES: O[C@@H]1[C@@H](CC2=CC=CC=C2)COC2=CC(=CC=C12)C1=CC(=CC=C1C(O)=O)C(F)(F)F, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Reason stopped: 
    see detailed description field
  
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of RA based upon the American college of Rheumatology 1987 revised
             criteria

          -  Active disease at Screening

          -  Stable dose of methotrexate between 10-25 mg/week oral or parenteral

        Exclusion Criteria:

          -  A diagnosis of any other inflammatory or secondary, noninflammatory arthritis that, in
             the opinion of the Investigator, would interfere with disease activity assessments

          -  A history of hypersensitivity or allergic type reactions to cyclooxygenase inhibitors,
             opiates, aspirin or sulfonamides
Clinical trial NCT00636246 (phase 2, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: sertraline/[s,s]-reboxetine, sertraline/[s,s]-reboxetine, sertraline, sertraline, sertraline/[s,s]-reboxetine, placebo, sertraline/[s,s]-reboxetine, [s,s]-reboxetine monotherapy
SMILES: CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12, CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must fulfill the criteria for MDD without psychotic features as defined by
             DSMIV, based on clinical assessment and confirmed by Structural Clinical Interview for
             DSM-IV Axis I Disorder-Clinical Version (SCID-I) plus the MDD Specifiers included in
             the Research Version of SCID-I.

          -  HAM-D (17-item) ≥ 22 at Screening (Visit 1) and > 20 at Baseline (Visit 2).

          -  Minimum CGI-S ≥ 4 at Screening (Visit 1) and at Baseline (Visit 2).

        Exclusion Criteria:

          -  Known failure to satisfactory respond after adequate dose and duration (12 weeks) of
             treatment with clomipramine and one SSRI, or with two or more SSRIs.

          -  Subjects with > 20% HAM-D (17-item) improvement (decrease) from Screening (Visit 1) at
             Baseline (Visit 2).

          -  Subjects with uncorrected hypothyroidism or hyperthyroidism.